Company: RVRC
Filing Date: 2025-12-12
Form Type: S-1/A
Source: 0001213900-25-121070
Chunk: 86

Company: Revium Rx.
Filing Date: 2025-12-12
Form: S-1/A
Chunk 86
---
     
 Reference:                                                                                        
 Liposomal mupirocin holds promise for systemic treatment of invasive Staphylococcus aureus        
 infections; Oliver Goldmanna,, Ahuva Cern, Mathias Mueskenc, Manfred Rohdec, William Weissd,      
 Yechezkel Barenholzb,, Eva Medinaa https://doi.org/10.1016/j.jconrel.2019.11.007                  |

| 3. | Rabbit Model – Infective 
 Endocarditis             |

A rabbit model of MRSA endocarditis was employed
using 2.2–2.5 kg New Zealand white rabbits. Animals were infected with ~10⁵ CFU MRSA (MW2 strain) and randomized (n=8 per
group) into three groups: Nano-Mupirocin (25 mg/kg IV BID), free mupirocin (same dose), or saline control. After 3 days of treatment,
animals were euthanized, and bacterial counts were determined in vegetations, kidneys, and spleen. Nano-Mupirocin-treated animals showed
statistically significant reductions in bacterial counts across all tissues compared to controls.

| Figure 3: Rabbit survival.                                                     
 Percent survival of rabbits in endocarditis study across the treatment groups. |     | Figure                                                                                                                       
 4: Rabbit PK Profile. Mupirocin plasma concentrations after IV administration of 25 mg/kg Nano-mupirocin vs. free mupirocin. |

Reference: Ahuva Cern, Ayelet Michael-Gayego, Yaelle Bavli, Erez Koren, Amiram Goldblum, Allon E. Moses, Yan Q. Xiong and Yechezkel Barenholz* Nano-mupirocin: enabling the parenteral activity of mupirocin DOI 10.1515/ejnm-2016-0006

<div align='center'>52</div>

| 4. | Murine                                                 
 Model – Necrotizing Fasciitis (Streptococcus pyogenes) |

A dose–response study was conducted in
a mouse model of necrotizing fasciitis using group A Streptococcus (GAS). Mice (n=6 per group) received a single IV dose of Nano-Mupirocin
(1.1–57 mg/kg) one hour post-infection. Survival was monitored for 5 days. All untreated mice died within 48 hours.